Background. Infection with parechovirus type 3 (PeV3) can cause severe neurologic and sepsis-like illness in young infants; clinical and epidemiologic descriptions have been limited. We aimed to characterize PeV3 illness and explore risk factors for acquisition in a cluster of neonatal cases at Children's Mercy Hospital in Kansas City, Missouri.
The genus Parechovirus in the family Picornaviridae comprises 2 species, Parechovirus A (formerly human parechovirus) and Parechovirus B (formerly Ljungan virus) [1] . Parechovirus A infections are associated with a variety of clinical manifestations that range from asymptomatic [2] to severe and include mild respiratory illness [2] , rash [3, 4] , gastroenteritis [5] , myocarditis [6] , encephalitis [4] , meningitis [7] , and sepsis-like illness [7, 8] . They are thought to be very common in the community [2, 9] ; most symptomatic infections occur in infants younger than 6 months [10, 11] . Parechovirus A has been reported in neonates as young as 2 days [12] , but reports of infection in the first week of life are rare.
To date, 19 Parechovirus A types have been detected worldwide [1, 13, 14] ; parechovirus type 1 (PeV1) and PeV3 are typically the most commonly detected virus types [9, 15, 16] . Although PeV diagnostics are not widely available in the United States, typed viruses can be reported passively to the National Enterovirus Surveillance System (NESS) [17] . During 2009 to 2013, PeV3 was the most common PeV type reported to the NESS, constituting 12.3% (223 of 1819) of all PeV and enterovirus reports [17] . Similar to enterovirus infections, central nervous system infections with PeV3 typically occur in late summer and fall [9, 18] .
In August 2014, Children's Mercy Hospital in Kansas City, Missouri (CMKC), notified the Centers for Disease Control and Prevention (CDC) of young infants and neonates experiencing seizures associated with PeV meningitis; initial sequencing at the CDC identified PeV3 in cerebrospinal fluid (CSF). Although PeV3 has been associated with sepsis-like illness, meningitis, and encephalitis [18] , type-specific data are limited, and the epidemiology in very young infants is not well defined. Here, we aim to describe the epidemiologic and clinical features of these PeV3 cases and to explore possible risk factors for acquisition of infection.
PATIENTS AND METHODS

Case Definition
CMKC is a large pediatric tertiary referral hospital in Kansas City that serves residents of neighboring states. Since 2010 at CMKC, CSF from all infants aged <180 days with signs of meningitis or sepsis-like illness and submitted for enterovirus testing have also been routinely tested for PeV by reverse-transcriptase polymerase chain reaction (RT-PCR). For this investigation, PeV-positive specimens were subsequently typed at the CDC. We defined a case-patient as any infant aged <180 days at CMKC with CSF confirmed to be PeV3-positive according to molecular sequencing results from the CDC between June 1 and November 1, 2014.
Virologic Investigation
PeV RT-PCR
Total nucleic acid (TNA) was extracted from 200 µl of CSF or stool suspensions (diluted 1:5 in distilled water) using an easy-MAG automated nucleic acid system (BioMérieux, Durham, NC) and eluted in 55 µl of Tris-EDTA buffer. The TNA extracted from CSF was tested by a 2-step pan-PeV and pan-enterovirus real-time RT-PCR on a 7500 fast real-time PCR system (Applied Biosystems, Foster City, CA) as described previously [19] . Specimens that tested PeV positive by RT-PCR at CMKC were subsequently sent to the CDC for confirmation and typing.
Virus Typing and Phylogenetic Analysis
At the CDC, TNA was tested by a pan-PeV nested RT-PCR that targets the PeV VP1 region [20] . Complete VP1 sequences from specimens that tested positive were typed [20] and then analyzed by the neighbor-joining and maximum-likelihood methods using MEGA version 6.0 [21] . Evolutionary distances (Kimura 2-parameter method) were calculated in units of the number of base substitutions per site. Five hundred bootstrap replicates were performed. Nucleic acid and deduced amino acid genetic distances for complete VP1 nucleotide sequences were calculated from alignments produced with MegAlign (DNASTAR 12.3.1, Madison, WI).
Epidemiologic Investigation
Because this investigation was part of a public health response, it was determined to be nonresearch by the CDC and therefore not subject to CDC institutional review board review.
Medical Chart Abstraction
For each infant with PeV-positive CSF, we abstracted demographic and clinical data from the CMKC medical chart. We collected information on symptoms, treatment, clinical course, laboratory findings, and imaging results.
Birth Chart Review
Because some case-patients were aged <2 weeks at illness onset, we also performed chart abstractions at the hospital in which the infant was born. We collected information regarding the mother's medical history, labor, delivery, and follow-up and regarding the infant's delivery and neonatal care. Because our investigation included case-patients from both Kansas and Missouri, birth chart reviews were coordinated through the appropriate health department. Birth chart review was performed for all case-patients identified before August 19, 2014 . For case-patients identified after this date, because of personnel availability, we abstracted data for only those who were aged <2 weeks at illness onset.
Parent Interview
We performed face-to-face structured interviews with case-patients' parents or guardians who were willing to participate. We collected information regarding the mother's peripartum period, the infant's health before hospitalization with PeV infection, and the infant's surroundings, household contacts, and visits (professional or social) in the week before illness. Interviews were coordinated through the Kansas and Missouri state health departments. For case-patients identified before August 19, 2014 , family members were contacted by telephone using contact information from CMKC to establish a time and place for the face-to-face interview. We typically conducted interviews at the family home. For case-patients identified on or after August 19, 2014 , because of personnel availability, families were approached during the infant's hospitalization, and interviews were conducted on site at CMKC.
Stool Collection
To assess PeV shedding after illness, we collected soiled diapers from case-patients and from their siblings who required diapers, tested the stool for PeV by RT-PCR, and performed sequencing as described earlier. A single diaper from each case-patient was typically collected at the time of family interview, which means that the number of days between illness onset and diaper collection was different for each case.
Statistical Analyses
For medical chart abstraction of the infants' hospitalization period, we compared characteristics of infants who were admitted to the intensive care unit (ICU) with those who were not. For the assessment of characteristics of acquisition through birth chart review and parent interview, we performed basic descriptive analyses and compared infants admitted to the ICU with those who were not. Subsequently, because PeV had rarely been reported in infants in their first week of life, we also compared characteristics in case-patients ≤7 days of age at disease onset with those who were older. Differences in epidemiologic and clinical characteristics were assessed for significance using the Fisher exact or Wilcoxon rank-sum test, as appropriate. All data were analyzed using SAS 9.3 (SAS Institute, Inc., Cary, NC).
RESULTS
Between June 1 and November 1, 2014, 40 infants at CMKC had PeV-positive CSF. Virus typing confirmed that 35 of these 40 infants were positive for PeV3, and 1 infant was positive for PeV4. Among the 4 remaining infants, CSF from 3 infants tested negative by VP1 RT-PCR, and CSF from 1 infant tested PeV-positive by RT-PCR but no residual specimen was available for sequencing.
Epidemiologic and clinical features of the 35 case-patients with PeV3 infection are listed in Table 1 ; all of these infants were hospitalized. Overall, 51% (18 of 35) were male, and the median age at illness onset was 24 days (range, 5-56 days). Common Inconsolable crying 0 (0) 3 (11) 3 (9) 1.0000
Respiratory illness Cough 0 (0) 5 (18) 5 (14) .5585
Runny nose 0 (0) 4 (14) 4 (11) .5620
Difficulty breathing 3 (43) 0 (0) 3 (9) .0053
Rales/crackles/crepitations 1 (14)
Retractions/nasal flaring 1 (14) Values shown are number (percent) or median (range). The following symptoms were collected but not reported for any infants: redness in the hands and feet, ulcers or lesions in the mouth, myoclonic jerk, tremor, limb weakness, stiff neck, cranial nerve palsy, secretions, wheezing, frothy secretions from mouth, hemoptysis, bradycardia, variable heart rate, arrhythmia, constipation, conjunctivitis, bleeding, and lymphadenopathy.
symptoms included fever (>38.0°C, 91% , that were consistent with partial or generalized seizures. Peripheral blood and CSF cell counts were typical of those previously described for patients with PeV infection [11, 12, 22] ; peripheral white blood cell counts were not elevated, and a lack of CSF pleocytosis was found. The median length of stay was 3 days (range, 1-18 days). No deaths were reported. The lone PeV4-positive infant experienced fever and difficulty breathing but did not require intensive care and was discharged home after 3 days. The infant was 6 days old at illness onset.
Among
and were significantly younger than infants who did not require ICU admission (median, 27 days; range, 5-56 days; P = .0044). Three of the 7 infants who required ICU admission experienced difficulty breathing, and 2 of 7 had a temperature of <35°C. It should be noted that 6 of the 7 infants who required intensive care experienced seizures (as defined earlier); all 6 of them were treated with acyclovir, and CSF samples from all of them subsequently tested negative for herpes simplex virus. Magnetic resonance imaging was performed for 3 of these 6 infants, and the results were abnormal for all of them, with white matter changes noted. Electroencephalography was performed for 2 of the 6 infants; for 1 infant, cephalopathic changes consistent with severe encephalopathy were found, and for the other infant, multifocal epileptiform discharges were seen. The median length of stay in the ICU was 4 days (range, 1-17 days). Two of the 7 infants who required ICU were discharged on anticonvulsant medication.
Complete PeV3 VP1 sequences were obtained from 35 patient CSF specimens. Phylogenetic analyses of these sequences with neighbor-joining and maximum-likelihood algorithms (Figure 1 ) gave similar results and showed 2 PeV3 lineages cocirculating during the investigation period. The largest PeV3 lineage (found in 30 patients) shared 97.9% to 100% nucleotide identity (NT ID) (99.5%-100% amino acid identity [AA ID]), and the smaller PeV3 lineage (5 patients) shared 99.8% to 100% NT ID (100% AA ID). Genetic distances between the 2 lineages, using the 35 VP1 sequences, ranged from 94% to 95% NT ID (98.5%-99% AA ID). Case-patients who required ICU admission were infected with either lineage, as were case-patients who experienced seizures. All PeV3 VP1 sequences acquired for this study were submitted to GenBank and assigned accession numbers KX356610 through KX356655.
Stool specimens (n = 18) were available from 17 PeV3 case-patients after discharge from the hospital, and 8 of these specimens tested positive for PeV3 ( Figure 1) ; all CSF-stool pairs from individual patients exhibited ≥98.8% NT ID. Most infants provided a single stool specimen, and time between disease onset and the specimen-collection date varied among the infants. All specimens collected <25 days after onset (n = 7) tested positive for PeV3. In contrast, only 1 of 11 specimens collected beyond 25 days after disease onset (collected on day 43) tested positive for PeV3; the 10 PeV3-negative specimens were collected between 27 and 73 days after disease onset. One infant provided 2 specimens, 1 on day 24 after disease onset, which tested positive for PeV3, and 1 on day 44 after onset, which tested negative.
To understand the characteristics of infants with PeV3 infection and their families, we performed birth chart reviews and parent interviews ( Table 2) . One of the 35 case-patients with PeV3 infection was born and resided in Texas and was excluded. Among the remaining 34 case-patients, 26 met our criteria for birth chart review, including 22 case-patients whose Values are number/total number of infants for whom the information was known (percent) or median (range). infection status was detected before August 19, 2014, and 4 case-patients whose infection status was detected after this date and were aged <2 weeks at onset. Twenty-two (85%) of these 26 birth chart reviews were completed. Parents of 23 (68%) of the 34 case-patients agreed to be interviewed; the median time between illness onset and the interview date was 24 days (range, 1-74 days). Both birth chart reviews and interviews were available for 16 cases. Birth chart reviews to explore mother and child health at delivery were unrevealing; for example, most births were uncomplicated, case-patients were not born prematurely, and the mothers were not reported as being febrile during delivery or in the week before. Parent interviews revealed that almost half of the case-patients (11 of 23) had a household contact who was ill during the week before disease onset. Ill contacts (n = 20) typically experienced symptoms representative of mild respiratory (n = 15) or gastrointestinal (n = 5) illness or had a rash (n = 2); the specific illness of 1 contact was not described. Most (21 of 23) of the infants had a household contact aged <11 years; the median age of these contacts was 3 years (range, 13 months to 10 years). Ten case-patients had a household contact aged <11 years who was ill during the week before onset. Stool specimens were available from 7 contacts of 6 case-patients. Siblings of 2 case-patients had PeV3-positive stool, and both case-patient (CSF)-sibling (stool) pairs exhibited ≥99.8% NT ID ( Figure 1) ; 1 sibling was reported to have developed a rash after the case-patient was discharged from CMKC, and the sibling of the other case-patient reported no symptoms. For 4 of the case-patients with PeV3 infection, a family history of neurological issues was reported, including history of seizures, attention-deficit hyperactivity disorder, and multiple sclerosis; 1 of these 4 patients experienced seizures during the hospitalization for PeV3 infection.
When we compared PeV3-positive case-patients aged ≤7 days (n = 5; listed in Table 3 ) with older case-patients, no apparent differences were observed in the data from the birth chart reviews or parent interviews, apart from the infant's birth hospital. Four (80%) of the 5 infants whose illness onset occurred in their first week of life were born at the same hospital (hospital A) within a period of 34 days. In contrast, only 2 (10%) of 20 case-patients who were >7 days old at illness onset were delivered at hospital A. Viruses from the 4 infants delivered at hospital A were part of the larger lineage and exhibited ≥99.7% NT ID.
DISCUSSION
We provide here a clinical and epidemiologic description of PeV3 infection in young infants and, by typing all available specimens, have provided an in-depth type-specific disease characterization. We show that PeV3 can cause severe neurologic illness in neonates and, in some cases, associated white matter changes. All infants who required intensive care became ill during their first 3 weeks of life and were significantly younger than those who were not admitted to the ICU.
Our clinical findings are consistent with data from previous PeV investigations. We found that common symptoms during PeV3 infection include fever [7, 9, 11, 12] , tachycardia [11] , poor feeding [7] , irritability [7, 9, 11, 12] , mottled skin [23] , and rash [9] . Severe PeV3 infections that required intensive care management were more common in younger infants (aged <3 weeks) in our investigation, as previously reported for untyped PeV infections [7] . We also identified seizures [3, 11, 24] associated with white matter changes as an important presentation, which was observed in 7 of 34 infants (6 of 7 in the ICU). As expected, all infants in our investigation who presented with seizures were evaluated for HSV infection and empirically treated with intravenous acyclovir. At CMKC, acyclovir treatment was stopped once the infant tested negative for HSV and positive for PeV. By comparison, CMKC detected only 1 infant (aged <30 days) with central nervous system HSV infection during the investigation period. A wider availability of diagnostics for PeV could lead to more judicious use of acyclovir in this very young and vulnerable population. Furthermore, infection outcomes vary substantially among patients with HSV and those with PeV. Unlike the potentially fatal neurologic complications of HSV infection in infants [25] , most infants in our investigation who were infected with PeV3 were discharged from the hospital in healthy condition after several days. Although longer-term neurologic sequelae after PeV infection have been observed [7, 26] , we did not assess long-term outcomes in this investigation. In addition, all case-patients in our investigation survived, although PeV3 infection has been associated with rare fatalities [27, 28] .
Consistent with previous reports that suggested that older siblings might pose a risk for PeV exposure [29] , results of our parent interviews indicated that almost half of all case-patients had ill household contacts aged <11 years. However, data from households without recognized PeV3 infection were not available for comparison. Results of previous retrospective studies have suggested that PeVs are a common source of illness in the community; PeV has been detected in 3% to 17% of CSF specimens from hospitalized infants [12, 22, 30, 31] , 13% of blood specimens from infants who required intensive care for late-onset sepsis [32] , 3.7% of plasma specimens from children who presented to an emergency department [33] , and 16.3% of stool specimens from children who presented to a medical center [10] . Despite these high estimates, PeVs often go undetected because of mild or asymptomatic presentations [2, 34] combined with limited application of available diagnostic tests. Although data on PeV3 circulation are limited, our cases occurred mostly within the proposed PeV3 season (late summer and fall) [9, 18] .
A subset of case-patients who became ill in their first week of life were of particular concern, because infection in this age group had been reported only rarely before this investigation. To explore the possibility of perinatal infection, maternal demographics and health at delivery were reviewed closely using labor and delivery charts, but this review was unrevealing. Maternal age has been suggested to be associated with severity of illness [35] , but we did not detect such an association.
We noted that 4 of 5 infants aged ≤7 days at illness onset were delivered at hospital A within a similar time period. Although it was not possible to distinguish between infections acquired in the healthcare setting versus those acquired in the community, this finding supports the recently reported possibility of healthcare-associated acquisition of PeV3 infection [13] . By comparison, it has been known for some years that PeV1 (previously named echovirus 22) can be transmitted within healthcare settings and can cause respiratory [36] or gastrointestinal [37] illness.
PeVs have been detected in a variety of specimens, including those from respiratory secretions [38] and stool [2, 10, 39] . We found that the stool of PeV3 case-patients could test positive 43 days after illness onset. By comparison, in infants followed longitudinally in previous investigations, the median duration of shedding was 51 [2] to 58 [39] days. Prolonged shedding after symptom resolution highlights the need for constant vigilance in infection-prevention and -control practices.
Phylogenetic clustering of the PeV3 VP1 sequences indicated cocirculation of 2 PeV3 strains, which differed by ≥5% NT ID, among patients treated at CMKC. Cocirculation of different PeV3 lineages had not been observed in PeV3 outbreaks previously, but it is common in large outbreaks of enterovirus disease [40] . This observation in a local PeV3 outbreak might be attributable to the large catchment area of CMKC. Severe illness was observed in both PeV3 clusters.
Our investigation was subject to several limitations. First, PeV testing is specialized, and its availability is limited. By directing testing toward CSF specimens from hospitalized infants aged <6 months, CMKC focuses on young infants and the more severe end of the clinical spectrum; therefore, the generalizability of these results is unknown. Second, parent interviews might have been subject to recall issues, especially for the families of infants who became ill earlier in the season. Last, we were not able to sequence 5 of the 40 original CSF specimens collected; the 5 infants from whom the specimens were not collected were aged ≥18 days, but no other differences were noted.
CONCLUSION
PeV3 should be considered alongside HSV, enteroviruses, and other pathogens as a cause of sepsis-like illness and meningitis in young infants. In addition to informing clinical management, expanded testing for PeVs might allow for a better understanding of virus circulation and disease burden.
